Candesartan
- Generic Name
- Candesartan
- Brand Names
- Atacand, Atacand Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H20N6O3
- CAS Number
- 139481-59-7
- Unique Ingredient Identifier
- S8Q36MD2XX
- Background
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.
- Indication
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
- Associated Conditions
- Hypertension, NYHA Functional Class II-IV Heart Failure
Expression and Function of the Renin-Angiotensin System in the Esophagus
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Göteborg University
- Target Recruit Count
- 33
- Registration Number
- NCT02879721
- Locations
- 🇸🇪
Dept. of Gastrosurgical Research and Education, Inst. Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden
Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B
- Conditions
- Hypertension
- Interventions
- Drug: CKD-330 16/5mg - B
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT02811731
Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A
- Conditions
- Hypertension
- Interventions
- Drug: CKD-330 16/5mg - A
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT02801526
The Precision Hypertension Care Study
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDrug: Hydrochlorthiazide®Drug: Treatment XDrug: Treatment Y
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 280
- Registration Number
- NCT02774460
- Locations
- 🇸🇪
Uppsala University hospital, Internal medicine research, Oscar II, Uppsala, Sweden
Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy
- Conditions
- HypertensionCholesterolemia
- Interventions
- Drug: DP-R208 PlaceboDrug: Candesartan32mg Placebo
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 219
- Registration Number
- NCT02770261
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
DP-R208 Pharmacokinetic Study
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 37
- Registration Number
- NCT02709187
Clinical Trial to Compare the Pharmacokinetics of DP-R208
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 40
- Registration Number
- NCT02707224
Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 135
- Registration Number
- NCT02651870
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Emory University
- Target Recruit Count
- 77
- Registration Number
- NCT02646982
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Wesley Woods Center, Atlanta, Georgia, United States
Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects
- Conditions
- Healthy Male Subjects
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT02609711
- Locations
- 🇰🇷
Inha Univ. Hospital, Incheon, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.